Experimental Chronic Staphylococcal Osteomyelitis in Rabbits: Treatment with Rifampin Alone and in Combination with Other Antimicrobial Agents

The efficacy of rifámpin alone and in combination with sisomicin, cephalothin, sisomicin and cephalothin, or trimethoprim was measured in an experimental model of chronic osteomyelitis due to Staphylococcus aureus in rabbits. Single-drug regimens used for 28 days were relatively ineffective (bone st...

Full description

Saved in:
Bibliographic Details
Published in:Reviews of infectious diseases 1983-07, Vol.5, p.S491-S494
Main Author: Norden, C W
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antimicrobials
Bone and Bones - microbiology
Bone marrow
Bones
Cephalothin - therapeutic use
Drug Therapy, Combination
Infections
Medical treatment
Osteomyelitis
Osteomyelitis - drug therapy
Rabbits
Rifampin - therapeutic use
Session II
Sisomicin - therapeutic use
Staphylococcal Infections - drug therapy
Staphylococcus
Staphylococcus - isolation & purification
Staphylococcus aureus
Sterilization
Trimethoprim - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of rifámpin alone and in combination with sisomicin, cephalothin, sisomicin and cephalothin, or trimethoprim was measured in an experimental model of chronic osteomyelitis due to Staphylococcus aureus in rabbits. Single-drug regimens used for 28 days were relatively ineffective (bone sterilization rate, 5%-55%). Combinations of rifampin with other agents were more effective (bone sterilization rate, 75%-100%). The combination of rifampin, sisomicin, and cephalothin given for only 14 days sterilized the bones of all treated rabbits. Staphylococci isolated from the bones of rabbits that had received rifampin alone or in combination with other antibiotics were highly resistant to rifampin; in contrast, these organisms remained sensitive to the other agents used. Results of in vitro studies of synergy correlated with in vivo results in some but not all instances. The results obtained with rifampin in the treatment of experimental chronic osteomyelitis caused by S. aureus suggest that clinical trials of this agent for the treatment of osteomyelitis in humans are warranted.
ISSN:0162-0886